Company Profile

Reata Pharmaceuticals Inc (AKA: Reata Discovery Inc)
Profile last edited on: 2/7/23      CAGE: 47XK0      UEI: ----------

Business Identifier: Drugs targeting molecular pathways regulating inflammation and cellular metabolism
Year Founded
2002
First Award
2005
Latest Award
2005
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2801 Gateway Drive Suite 150
Irving, TX 75063
   (972) 865-2219
   info@reatapharma.com
   www.reatapharma.com
Location: Single
Congr. District: 24
County: Dallas

Public Profile

Formerly known as Reata Discovery, Reata Pharmaceuticals, Inc. (NASDAQ:RETA) is a clinical stage biopharmaceutical company headquartered in Plano, TX with Labs in Irving, TX previously developing oral anti-inflammatories. Now working on novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation: experimental oral antioxidative and anti-inflammatory drugs. No longer SBIR-active orinvolved, the company is now developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and with AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : RETA
IP Holdings
75-99

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 1 NIH $100,000
Project Title: Discovering Small Molecules to Rescue SOD-1 folding

Key People / Management

  Warren Huff -- Founding Chief Executive Officer and President

  Ronald H Abrahams -- Senior Vice President, Operations

  Christiane Baud -- Director, Clinical Programs and Regulatory Affairs

  Dawn C Bir -- Chief Commercial Officer

  Elaine Castellanos -- Vice President of Finance and Accounting

  Charles Cook -- Vice President of CMC

  Robin Kral -- Vice President of Business Development

  Melissa Krauth -- Director, Program Management

  Colin Meyer -- Chief Medical Officer and Vice President of Product Development

  Joel Proksch -- Vice President of Regulatory and Development

  Mike Visnick -- Vice President of Discovery Chemistry

  Keith Ward -- Chief Development Officer

  W Christian Wigley -- Vice President of Research and Founding Scientist

  Jason Wilson -- Chief Financial Officer and Vice President of Strategy

  Michael D Wortley -- Chief Legal Officer